Renibus Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$111M
- Investors
-
5
Renibus Therapeutics General Information
Description
Operator of a biotechnology company intended to develop novel pharmacologic therapies. The company develops novel therapeutics for post-operative surgery complications as well as acute and chronic kidney disease and offers advances for the prevention and management of such diseases, enabling the healthcare sector to access novel therapies to treat various types of health problems and transform outcomes in cardiothoracic surgical patients.
Contact Information
Website
www.renibus.comCorporate Office
- 181 Grand Avenue
- Suite 225
- Southlake, TX 76092
- United States
Corporate Office
- 181 Grand Avenue
- Suite 225
- Southlake, TX 76092
- United States
Renibus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B1) | 17-Jul-2025 | $111M | Completed | Clinical Trials - Phase 3 | ||
| 3. General Corporate Purpose | 14-Nov-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series A) | 17-Feb-2022 | $34.6M | $45.8M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC | 02-May-2016 | $11.2M | $11.2M | Completed | Startup |
Renibus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 13,565,892 | $0.001000 | 8% | $2.58 | $2.58 | 1x | $2.58 | 18.2% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Renibus Therapeutics Comparisons
Industry
Financing
Details
Renibus Therapeutics Competitors (6)
One of Renibus Therapeutics’s 6 competitors is Bitterroot Bio, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bitterroot Bio | Venture Capital-Backed | Palo Alto, CA | ||||
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Cadrenal Therapeutics | Formerly Angel backed | Ponte Vedra Beach, FL | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA |
Renibus Therapeutics Patents
Renibus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213609-A1 | Pharmaceutical compositions for the treatment of salicylate toxicity | Pending | 04-Apr-2025 | ||
| US-20260157962-A1 | Compositions of stannic protoporfin for long term stability and container closure systems for storing stannic protoporfin | Pending | 09-Dec-2024 | ||
| WO-2026128454-A1 | Compositions of stannic protoporfin for long term stability and container closure systems for storing stannic protoporfin | Pending | 09-Dec-2024 | ||
| WO-2025165353-A1 | Novel stannic protoporfin compositions, methods of making, and uses thereof | Pending | 31-Jan-2024 | ||
| US-20250242033-A1 | Novel stannic protoporfin compositions, methods of making, and uses thereof | Pending | 07-Nov-2023 | A61K33/26 |
Renibus Therapeutics Signals
Renibus Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bios Partners | Venture Capital | Minority | ||
| Cathexis Ventures | Corporate Venture Capital | Minority | ||
| Green Park & Golf Ventures | Venture Capital | Minority | ||
| AG Collective Capital | Venture Capital | Minority | ||
| CKG Management | Venture Capital | Minority |
Renibus Therapeutics Investments (1)
Renibus Therapeutics’s most recent deal was a Corporate Asset Purchase with Tricida (IP and Inventory Assets) for . The deal was made on 21-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tricida (IP and Inventory Assets) | 21-Feb-2023 | Corporate Asset Purchase | Buildings and Property |
Renibus Therapeutics FAQs
-
When was Renibus Therapeutics founded?
Renibus Therapeutics was founded in 2015.
-
Where is Renibus Therapeutics headquartered?
Renibus Therapeutics is headquartered in Southlake, TX.
-
What is the size of Renibus Therapeutics?
Renibus Therapeutics has 29 total employees.
-
What industry is Renibus Therapeutics in?
Renibus Therapeutics’s primary industry is Drug Discovery.
-
Is Renibus Therapeutics a private or public company?
Renibus Therapeutics is a Private company.
-
What is the current valuation of Renibus Therapeutics?
The current valuation of Renibus Therapeutics is .
-
What is Renibus Therapeutics’s current revenue?
The current revenue for Renibus Therapeutics is .
-
How much funding has Renibus Therapeutics raised over time?
Renibus Therapeutics has raised $187M.
-
Who are Renibus Therapeutics’s investors?
Bios Partners, Cathexis Ventures, Green Park & Golf Ventures, AG Collective Capital, and CKG Management have invested in Renibus Therapeutics.
-
Who are Renibus Therapeutics’s competitors?
Bitterroot Bio, Phathom Pharmaceuticals, Protagonist Therapeutics, Cadrenal Therapeutics, and Ardelyx are some of the 6 competitors of Renibus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process